| Literature DB >> 25277218 |
Changchuan Li, Chi Zhang, Maolin Zhang, Yue Ding1.
Abstract
BACKGROUND: Subtrochanteric femoral shortening osteotomy is a crucial procedure to prevent nerve injury in total hip arthroplasty for severe developmental dysplasia of the hip. Transverse osteotomy was first applied, and other modified methods have also been reported. Each has its own advantages and limitations, but no definitive conclusions regarding differences in outcomes have been reached to date.Entities:
Mesh:
Year: 2014 PMID: 25277218 PMCID: PMC4201680 DOI: 10.1186/1471-2474-15-331
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Figure 1Schematic illustration of different methods of subtrochanteric femoral shortening osteotomy. (a) transverse (b) oblique (c) double-chevron (d) step-cut.
Figure 2Flowchart of the study selection process.
Characteristics of included studies
| Study | Country | Mean age (range), year | Sex, Female % | Crowe classification | Total, hips/patients | Method of osteotomy | Mean follow-up (range), years | Nonunion, hips | Nerve injury, hips | Revision | Dislocation | Deep infection | Harris hip score | Limb-length discrepancy | Acceptable discrepancy, patients | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-operative | Post-operative | Pre-operative | Post-operative | ||||||||||||||
| Becker, 1995 | USA | 61 (48–72) | N/A | IV | 7/4 | Double-chevron | 2.7 (0.3-6) | 0 | 0 | 1 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Reikeraas, 1996 | Norway | 54 (17–67) | 93.8 | IV | 25/19 | Transverse | (3–7) | 0 | 1 | N/A | N/A | N/A | 43 | 93 | N/A | N/A | N/A |
| Yasgur, 1997 | USA | 42 (22–77) | 77.8 | IV | 9/8 | Transverse | 3.6 (2–7) | 1 | 0 | 1 | 1 | N/A | N/A | N/A | N/A | 1.5 | N/A |
| Chareancholvanich, 1999 | USA | 51 (21–74) | N/A | N/A | 15/11 | Double-chevron | 5.5 (2–8.5) | 0 | 0 | N/A | 0 | N/A | N/A | N/A | 3.9 | 1.4 | N/A |
| Zadeh, 1999 | UK | 49 (34–61) | 71.4 | I, II & IV | 7/7 | Transverse | 2.6 (1.3-5.0) | 1* | N/A | N/A | N/A | N/A | 44 | 91 | N/A | N/A | N/A |
| Bruce, 2000 | Australia | 53 (26–77) | N/A | III & IV | 6/5 | Transverse | 4.7 (0.5-7.2) | 0 | 0 | N/A | N/A | 0 | 31 | 81 | N/A | N/A | N/A |
| Ozturkmen, 2002 | Turkey | N/A | N/A | IV | 7/7 | Step-cut | N/A | 1 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sener, 2002 | Turkey | 43 (26–64) | 95.7 | III & IV | 28/23 | Step-cut | 4.0 (0.6-7.7) | 2 | 2 | 0 | 0 | 0 | 36.9 | 95.3 | N/A | N/A | 19 |
| Decking, 2003 | Germany | 47 (19–58) | 70.0 | II.III & IV | 12/10 | Step-cut | 5.1 (1.6-10) | 0 | 1 | 1 | 0 | 0 | 36 | 82 | 5.4 | 1.3 | N/A |
| Masonis, 2003 | Canada | 48.2 (21–70) | 84.2 | III & IV | 21/19 | Transverse | 5.8 (2.0-11.2) | 2 | 0 | 3 | 3 | 0 | 32.5 | 73.6 | N/A | N/A | N/A |
| Erdemli, 2005 | Turkey | 44 (28–61) | 100.0 | IV | 25/22 | Step-cut in 3 hips | 5 (2–10) | 0 | 0 | N/A | N/A | 0 | N/A | N/A | N/A | N/A | N/A |
| Transverse in 22 hips | 1 | 0 | N/A | N/A | 0 | N/A | N/A | N/A | N/A | N/A | |||||||
| Bernasek, 2007 | USA | 43 (17–67) | 91.3 | I.II.III & IV | 23/20 | Transverse | 8 (5–14) | 0 | 0 | 1 | 4 | 0 | 42 | 82 | N/A | N/A | N/A |
| Gotze, 2007 | Germany | 41.7 (29–64) | N/A | III & IV | 7/7 | Transverse | 1.5 | 0 | N/A | N/A | N/A | N/A | 43 | 77 | N/A | N/A | N/A |
| Makita, 2007 | Japan | 59.6 (42–76) | 100.0 | IV | 11/11 | Step-cut | 5.4 (2.5-14.1) | 0 | 2 | 1 | 1 | 0 | N/A | N/A | 4.7 | 1.2 | 7 |
| Park, 2007 | Korea | 44.8 (20–66) | N/A | III & IV | 24/23 | Transverse | 4.7 (2.0-7.6) | 3 | 0 | 1 | 1 | N/A | 35.6 | 81.7 | N/A | N/A | 21 |
| Krych, 2009 | USA | N/A | N/A | IV | 28/24 | Transverse | 4.8 | 2 | 0 | N/A | 4 | N/A | 43 | 89 | N/A | N/A | N/A |
| Nagoya, 2009 | Japan | 55 (44–69) | 94.4 | IV | 20/18 | Transverse | 8.1 (4–11.5) | 0 | 0 | 2 | 0 | 0 | N/A | N/A | N/A | 1.2 | N/A |
| Howie, 2010 | UK | 47.3 (26–75) | N/A | III & IV | 35/28 | Transverse | 5.6 (2–14) | 1 | 2 | 7 | 3 | 1 | N/A | N/A | N/A | N/A | N/A |
| Reikeraas, 2010 | Norway | 48 (16–79) | 70.8 | III & IV | 65/46 | Transverse | 13 (8–18) | 2 | 2 | 11 | 1 | N/A | N/A | 87 | N/A | 1.0 | N/A |
| Togrul, 2010 | Turkey | 42.3 (33–52) | 85.7 | III & IV | 21/14 | Transverse | 3.4 (2.0-5.3) | 0 | 0 | N/A | 2 | 0 | N/A | N/A | N/A | 0.3 | N/A |
| Akiyama, 2011 | Japan | 58.9 (42–77) | 90.9 | III & IV | 15/11 | Transverse | 6.3 (2.8-10.4) | 3 | 0 | 3 | 2 | N/A | N/A | N/A | 2.9 | 0.3 | 11 |
| Charity, 2011 | UK | 51 (33–75) | 100.0 | IV | 18/15 | Transverse | 9.5 (4.3-14) | 1 | 1 | 4 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Dallari, 2011 | Italy | 52 (34–66) | 76.9 | IV | 33/26 | Step-cut in 14 hips | 7.3 (2.2-15.3) | 0 | N/A | N/A | N/A | N/A | N/A | N/A | 7.0 | 3.0 | N/A |
| Oblique in 19 hips | 1 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||||
| Kawai, 2011 | Japan | 64.8 (57–73) | 100 | IV | 19/12 | Transverse | 3.2 (0.5-8) | 0 | 0 | N/A | 0 | 0 | N/A | N/A | N/A | N/A | N/A |
| Kilicarslan, 2011 | Turkey | 46 (20–72) | N/A | III & IV | 45/31 | Transverse | 7.2 (2.0-10.1) | 5 | 0 | N/A | 2 | N/A | N/A | N/A | 2.9 | 1.4 | N/A |
| Starker, 2011 | Germany | 44.6 | 83.3 | IV | 25/20 | Step-cut | N/A | 0 | N/A | N/A | N/A | N/A | N/A | 90 | N/A | 0.8 | 20 |
| Takao, 2011 | Japan | 60 | 92.0 | IV | 33/25 | Step-cut | 8 (5–11) | 0 | 0 | 1 | 2 | N/A | N/A | N/A | 5.1 | 2.8 | N/A |
| Zhong, 2011 | China | 45.2 (36–56) | 100.0 | IV | 36/28 | Transverse | 4.4 (2.3-7.8) | 0 | 0 | N/A | 0 | 0 | 39 | 87 | 5.7 | 0.6 | N/A |
| Baz, 2012 | Turkey | 41.6 (24–56) | 86.7 | IV | 21/15 | Transverse | 4.9 (3–8) | 0 | 1 | 2 | 2 | 0 | 36.2 | 90.8 | N/A | N/A | N/A |
| Hasegawa, 2012 | Japan | 58.5 (48–72) | 100.0 | IV | 15/N/A | Step-cut | 10.2 (5–20) | 0 | 1 | 4 | 3 | 0 | 56 | 85 | 3.8 | 1.4 | N/A |
| Semenowicz, 2012 | Poland | 53.4 | 100.0 | IV | 10/10 | Step-cut | 2.3 | 0 | 0 | N/A | N/A | N/A | 43.7 | 86 | N/A | N/A | N/A |
| Kilicoglu, 2013 | Turkey | 43 (27–60) | 95.0 | IV | 20/16 | Oblique | 6.8 (3.7-10.3) | 1* | 0 | 2 | 3 | N/A | 50 | 83 | N/A | 1.0 | N/A |
| Li WB, 2013 | China | N/A | 100 | IV | 5/5 | Transverse | N/A | 0 | 0 | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Li YW, 2013 | China | 54 (41–75) | 83.3 | IV | 22/18 | Double-chevron | 8 (3–12) | 0 | 0 | 0 | 0 | 0 | 30 | 91.9 | 2.5 | 1 | 18 |
| Oe, 2013 | Japa | 64.9 (35–80) | 96.2 | IV | 34/26 | Transverse | 5.2 (3–10) | 0 | 0 | 0 | 3 | 0 | N/A | N/A | 4.7 | 1.2 | 26 |
| Sun, 2013 | China | 47 (38–65) | 63.3 | IV | 32/27 | Transverse | 4 (0.6-7) | 0 | 1 | 0 | 0 | 0 | 41.7 | 89.1 | N/A | N/A | N/A |
| Oinuma, 2014 | Japan | 61.5 (46–73) | 100 | IV | 12/9 | Transverse | 3.7 (1.5-6.3) | 0 | 0 | 0 | 1 | 0 | N/A | N/A | N/A | N/A | N/A |
| Total | / | 50.0 | 88.1 | / | 791/N/A | / | / | 27 | 14 | 45 | 38 | 1 | / | / | / | / | / |
N/A: not available.
*Delayed union that needs a second procedure.
Figure 3Forest plot of all eligible studies for nonunion rate.
Outcomes of meta-analysis and subgroup analysis
| Outcome of interest | No. of studies | No. of hips | No. of events | Pooled estimate | 95% CI | Study heterogeneity | ||
|---|---|---|---|---|---|---|---|---|
| χ2 | I2 |
| ||||||
| Nonunion | 39 | 791 | 27 | 3.79% | (2.60%, 5.20%) | 39.25 | 3.2% | 0.414 |
| Modified subgroup | 15 | 241 | 5 | 3.03% | (1.29%, 5.51%) | 8.29 | 0.0% | 0.874 |
| Transverse subgroup | 24 | 550 | 22 | 4.14% | (2.67%, 5.20%) | 30.34 | 24.2% | 0.140 |
| Nerve palsy | 33 | 712 | 14 | 2.63% | (1.60%, 3.87%) | 21.9 | 0.0% | 0.910 |
| Dislocation | 27 | 641 | 38 | 5.88% | (4.22%, 7.80%) | 42.35 | 36.2% | 0.030 |
| Modified subgroup | 9 | 163 | 9 | 5.47% | (2.57%, 9.36%) | 12.99 | 38.4% | 0.112 |
| Transverse subgroup | 18 | 478 | 29 | 6.03% | (4.14%, 8.29%) | 29.28 | 38.5% | 0.045 |
| Revision | 22 | 482 | 45 | 8.90% | (6.56%, 11.50%) | 45.57 | 53.9% | 0.001 |
| Modified subgroup | 8 | 148 | 10 | 6.66% | (3.31%, 11.12%) | 14.04 | 50.1% | 0.050 |
| Transverse subgroup | 14 | 334 | 35 | 9.96% | (7.06%, 13.35%) | 29.99 | 56.7% | 0.005 |
| Limb-length discrepancy | 7 | 132* | 10* | 6.31% | (2.90%, 11.00%) | 18.37 | 67.3% | 0.005 |
| Modified subgroup | 4 | 72 | 8 | 9.02% | (3.64%, 16.40%) | 13.86 | 78.4% | 0.003 |
| Transverse subgroup | 3 | 60 | 2 | 3.72% | (0.50%, 9.72%) | 2.83 | 29.3% | 0.243 |
| HHS improvement | 17 | 337 | / | 26.79% | (26.35%, 27.32%) | 654.87 | 97.6% | <0.001 |
| Modified subgroup | 6 | 107 | / | 27.41% | (26.52%, 28.31%) | 569.55 | 99.1% | <0.001 |
| Transverse subgroup | 11 | 230 | / | 26.61% | (25.99%, 27.14%) | 82.56 | 87.9% | <0.001 |
| Deep infection | 19 | 393 | 1 | 1.34% | (0.46%, 2.67%) | 2.24 | 0.0% | 1.000 |
*Number of patients; CI: confidential interval.
Figure 4Forest plot of all eligible studies for nerve palsy rate.
Figure 5Forest plot of all eligible studies for dislocation rate.
Figure 6Forest plot of all eligible studies for revision rate.
Outcomes of meta-regression analysis
| Nonunion | Nerve palsy | Revision | Dislocation | HHS improvement | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Co. |
| Co. |
| Co. |
| Co. |
| Co. | |
| Method of osteotomy (modified vs. transverse) | 0.472 | −0.030 | 0.240 | 0.051 | 0.653 | −0.033 | 0.735 | −0.020 | 0.562 | −0.025 |
| Country (western vs. eastern) | 0.731 | 0.013 | 0.272 | 0.042 | 0.010 | 0.169 | 0.592 | 0.029 | 0.819 | −0.010 |
| Mean Age | 0.141 | −0.004 | 0.734 | 0.000 | 0.760 | −0.001 | 0.919 | 0.000 | 0.736 | −0.001 |
| Mean Age (<49y vs. ≥ 49y) | 0.302 | 0.042 | 0.958 | −0.002 | 0.980 | 0.002 | 0.948 | −0.004 | 0.940 | 0.004 |
| Proportion of female | 0.845 | 0.000 | 0.587 | 0.000 | 0.721 | 0.001 | 0.367 | 0.003 | 0.290 | −0.002 |
| Proportion of female (<93% vs. ≥ 93%) | 0.645 | 0.019 | 0.833 | −0.009 | 0.793 | 0.021 | 0.723 | 0.026 | 0.143 | 0.073 |
| Follow up | 0.906 | 0.000 | 0.700 | 0.003 | 0.074 | 0.021 | 0.937 | 0.000 | 0.408 | −0.008 |
| Follow up (≤5y vs.>5y) | 0.937 | 0.003 | 0.871 | −0.006 | 0.014 | −0.163 | 0.391 | −0.046 | 0.354 | 0.042 |
| Year of publication (2010 or before vs. after 2010) | 0.187 | 0.051 | 0.244 | 0.044 | 0.300 | 0.071 | 0.716 | 0.019 | 0.504 | 0.028 |
HHS: Harris hip score; Co.: meta-regression coefficient.
Figure 7Begg’s funnel plot of all eligible studies for (a) nonunion rate (b) nerve palsy (c) dislocation rate (d) revision rate.